Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31246480 | 0.95 | PARP1 (0.43) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL22165322 | 0.89 | C5AR1 (0.39) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL1832511 | 0.86 | PARP1 (0.47) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL31536045 | 0.85 | PARP1 (0.47) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL30338938 | 0.84 | ADORA1 (0.48) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL19959253 | 0.84 | ADORA1 (0.48) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL29899503 | 0.83 | PARP1 (0.46) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL24730851 | 0.83 | PARP1 (0.44) | PARP1TNKS2PARP2ADORA1ESR2 | |
| SCHEMBL29108803 | 0.83 | C5AR1 (0.52) | C5AR1MTOR | |
| SCHEMBL20955091 | 0.83 | P2RX3 (0.49) | PARP1TNKS2PARP2ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260015363-A1 | SUBSTITUTED PYRIMIDINE-FUSED RING INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-20250376483-A1 | PRODRUGS OF PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540244-A1 | PRODRUGS OF PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119654320-A | Prodrugs of PAN-KRas inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024235876-A1 | PYRIDOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | FERNANDEZ CAPETILLO OSCAR (SE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023244600-A1 | PRODRUGS OF PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4262803-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116801883-A | Heteroaromatic ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022194192-A1 | HETEROAROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-09-22 | — | — | WO | disclosed |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| WO-2022133038-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015363-A1 | SUBSTITUTED PYRIMIDINE-FUSED RING INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF | KRAS, NRAS, HRAS | PARP1 1009/4885TNKS2 2354/4885PARP2 1812/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PARP1 1158/4885TNKS2 1301/4885PARP2 1147/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | PARP1 96/4885TNKS2 263/4885PARP2 247/4885 |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | PARP1 96/4885TNKS2 263/4885PARP2 247/4885 |
| US-20250376483-A1 | PRODRUGS OF PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | PARP1 230/4885TNKS2 554/4885PARP2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.